Orvepitant
- Generic Name
- Orvepitant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H35F7N4O2
- CAS Number
- 579475-18-6
- Unique Ingredient Identifier
- IIU6V0W3JD
- Background
Orvepitant has been used in trials studying the treatment of Depressive Disorder, Depressive Disorder, Major, Post-Traumatic Stress Disorder, and Posttraumatic Stress Disorder (PTSD).
- Associated Conditions
- -
- Associated Therapies
- -
A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03535662
- Locations
- 🇬🇧
Parexel Epcu, Harrow, Middlesex, United Kingdom
A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Registration Number
- NCT03464526
Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 132
- Registration Number
- NCT01000493
- Locations
- 🇺🇸
GSK Investigational Site, Middleton, Wisconsin, United States
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 343
- Registration Number
- NCT00880048
- Locations
- 🇨🇦
GSK Investigational Site, Gatineau, Quebec, Canada
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 328
- Registration Number
- NCT00880399
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Food and Relative Bioavailability Study
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00843011
- Locations
- 🇮🇹
GSK Investigational Site, Verona, Veneto, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath